Biologicals in childhood severe asthma: the European PERMEABLE survey on the status quo


Santos-Valente E., Buntrock-Dopke H., Abou Taam R., Arasi S., Bakırtaş A., Lozano Blasco J., ...Daha Fazla

ERJ OPEN RESEARCH, cilt.7, sa.3, 2021 (ESCI) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 7 Sayı: 3
  • Basım Tarihi: 2021
  • Doi Numarası: 10.1183/23120541.00143-2021
  • Dergi Adı: ERJ OPEN RESEARCH
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, BIOSIS, EMBASE, Directory of Open Access Journals
  • Gazi Üniversitesi Adresli: Evet

Özet

Introduction Severe asthma is a rare disease in children, for which three biologicals, anti-immunoglobulin E, anti-interleukin-5 and anti-IL4RA antibodies, are available in European countries. While global guidelines exist on who should receive biologicals, knowledge is lacking on how those guidelines are implemented in real life and which unmet needs exist in the field. In this survey, we aimed to investigate the status quo and identify open questions in biological therapy of childhood asthma across Europe.